Fibroblast growth factor can be measured in clinical practice using ELISA, with acceptable validity. Different from many metabolites and minerals, its value can differ by a thousand-fold between individuals, largely because of differences in kidney function and dietary habits. This wide range complicates the proper interpretation of the concentration of FGF23, both in terms of the appropriateness of a given value for a given estimated GFR, and in terms of estimating the magnitude of risk for clinical events, with which FGF23 is clearly associated. In this narrative review, the impact of kidney function, exposure to phosphate from diet, and novel emerging factors that influence FGF23 concentrations are discussed. These and yet to define determinants of FGF23 question the causality of the association of FGF23 with hard (cardiovascular) endpoints, as observed in several epidemiological studies.

中文翻译：

---

慢性肾脏疾病中FGF23的测量：它真正反映了什么？

可以使用ELISA在临床实践中测量成纤维细胞生长因子，并具有可接受的有效性。与许多代谢物和矿物质不同，其价值在个体之间可能相差千倍，这主要是由于肾脏功能和饮食习惯的差异。这种宽泛的范围使FGF23浓度的正确解释变得复杂，无论是对于给定的估计GFR的给定值的适当性，还是在估计与FGF23明显相关的临床事件的风险大小方面。在这篇叙述性综述中，讨论了肾脏功能的影响，饮食中磷酸盐的暴露以及影响FGF23浓度的新出现因素。这些但尚未定义FGF23的决定因素，质疑FGF23与硬性（心血管）终点之间的因果关系，